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ABSTRACT
Purpose. This international, multicenter, single-arm trial
assessed efficacy and safety of intralesional rose bengal
(PV-10) in 80 patients with refractory cutaneous or sub-
cutaneous metastatic melanoma.
Methods. Sixty-two stage III and 18 stage IV melanoma
patients with disease refractory to a median of six prior
interventions received intralesional PV-10 into up to 20
cutaneous and subcutaneous lesions up to four times over a
16-week period and were followed for 52 weeks. Objec-
tives were to determine best overall response rate in
injected target lesions and uninjected bystander lesions,
assess durability of response, and characterize adverse
events.
Results. For target lesions, the best overall response rate
was 51 %, and the complete response rate was 26 %.
Median time to response was 1.9 months, and median
duration of response was 4.0 months, with 8 % of patients
having no evidence of disease after 52 weeks. Response
was dependent on untreated disease burden, with complete
response achieved in 50 % of patients receiving PV-10 to
all of their disease. Response of target lesions correlated
with bystander lesion regression and the occurrence of
locoregional blistering. Adverse events were predomi-
nantly mild to moderate and locoregional to the treatment
site, with no treatment-associated grade 4 or 5 adverse
events.
Conclusions. Intralesional PV-10 yielded durable local
control with high rates of complete response. Toxicity was
confined predominantly to the injection site. Cutaneous
bystander tumor regression is consistent with an immuno-
logic response secondary to ablation. This intralesional
approach for local disease control could be complementary
to current and investigational treatments for melanoma.
Patients with regional metastatic melanoma (i.e., local,
in-transit, and satellite recurrence) have a long median
survival, but their clinical management can be challenging
due to disease heterogeneity and frequent and persistent
proliferation of lesions.1–5 Refractory lesions are often
highly unpleasant for the patient; can lead to ulceration,
bleeding, or infection; and can affect extensive areas for
prolonged intervals before distant metastasis.6 Some
patients with established visceral metastases also have
dermal disease and similarly troublesome symptoms.
Current treatment guidelines include surgical excision,
local ablation, intralesional therapy, and regional chemo-
therapy, along with targeted drugs (e.g., against the V600E
BRAF mutation).7 There are currently few drug therapies,
especially for BRAF wild-type patients, that can provide
rapid, sustained reduction of tumor burden with low
toxicity.
Rose bengal disodium (RB) has been used as an
intravenous liver function diagnostic and is still used as a
topical ophthalmic diagnostic.8,9 PV-10 (a sterile, non-
pyrogenic 10 % solution of RB in 0.9 % saline) is a small
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molecule agent for intralesional (IL) injection into tumors.
After IL injection, PV-10 accumulates in tumor lysosomes
resulting in rapid lysis of tumor cells.10 This primary
ablative effect may induce a secondary tumor-specific T
cell–mediated antitumor immune response.11,12 In a phase
1 study, a single IL dose of PV-10 was well tolerated,
with a best overall response rate (BORR) at 12 weeks of
55 %. Notably, 3 of 11 patients had no evidence of
recurrence for at least 28 months.13 Subsequently, this
phase 2 study was undertaken, allowing repeat dosing of
PV-10 and following patients for up to 52 weeks (clinical
trial NCT00521053).
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PATIENTS AND METHODS
Study Design
Eighty patients were enrolled onto this international,
multicenter, open-label, single-agent study. The governing
institutional ethics committee for each study center
approved the study protocol, and all patients provided
written informed consent. Eligible patients had biopsy-
proven confirmation of melanoma and at least one cuta-
neous or subcutaneous lesion C0.2 cm in diameter that
could accurately be measured by ruler/caliper or ultra-
sound. They received a single IL injection of PV-10 to
uniformly infiltrate each of up to 20 study lesions on day 0
(i.e.,B10 target and B10 nontarget dermal lesions) using
0.5 mL PV-10 per cm3 of lesion volume. Treatment could
be repeated at weeks 8, 12, and 16 for new nontarget
lesions or existing target or nontarget lesions not exhibiting
complete response. PV-10 was not injected into nodal or
visceral lesions. One or two additional measureable,
biopsy-confirmed dermal lesions could be designated for
assessment of bystander response and were followed but
not injected. Body mapping and digital photography with
lesion identification markers and reference scale were used
to accurately track all study lesions. Patients were followed
for 52 weeks after initial PV-10 treatment (i.e., for at least
36 weeks after their last possible PV-10 treatment).
Study evaluations, including lesion photography, were
performed at screening, on the day of PV-10 administra-
tion, at 1 day and 7 days after injection, and every 4 weeks
thereafter during the treatment portion of the study (i.e.,
through week 16), and during long-term follow-up at
weeks 24, 36, and 52. Radiologic assessments of visceral
disease status were performed every 12 weeks throughout
the study, and patients were transitioned into survival fol-
low-up if at any time the investigator identified clinical or
radiologic evidence of distant progression. No other mel-
anoma therapy was permitted during the study interval.
Treatment for concurrent or intercurrent illness, and wound
care or management of pain, were allowed at each inves-
tigator’s discretion. Adverse events (AEs) were monitored
over the study interval.
The study utilized a modified Fleming two-stage
design.14 Interim assessment upon accrual of the first 40
patients required an objective response in at least eight
patients to substantiate a true response rate between 10 and
30 %. Full accrual allowed testing of a projected 30 %
primary efficacy rate (95 % confidence interval 20–40).
Post hoc exploratory analyses were undertaken to under-
stand results in certain subgroups.
Criteria for Analyses
The primary end point of the study was BORR of
target lesions, with secondary end points of progression-
free survival (PFS) and duration of response, overall
survival (OS), by-lesion BORR, and bystander lesion
BORR, along with assessment of AEs, quality-of-life
(assessed using the EORTC QLQ-C30 instrument), lesion
pain (assessed via a 100 mm visual analog scale), and
pharmacokinetics.15–17
Response Evaluation Criteria in Solid Tumors (RE-
CIST) was modified (mRECIST) to allow: (1) designation
of cutaneous or subcutaneous lesions C0.2 cm in diameter
as target lesions; (2) up to 10 cutaneous and subcutaneous
target lesions to be followed; and (3) assessment of dis-
ease progression against baseline sum of longest
diameters of target lesions, thereby allowing clinically
insignificant progression (including locoregional appear-
ance of new cutaneous or subcutaneous nontarget lesions)
to be treated to week 16.18 Standard thresholds for per-
centage change in sum of longest diameters were used to
define complete response (CR), partial response (PR),
stable disease (SD), and progressive disease (PD). All
lesions specified at baseline were followed over the course
of the study with last observations carried forward for any
lesions not measurable at a visit; response assessment was
censored for missed visits. When eschar was reported, a
standard query was used to ascertain lesion status. An
example of measurable eschar that eclipsed baseline
measurement is illustrated in Fig. 1a. To mitigate such
artifacts and allow detection of regrowth after initial
ablation, the first formal response assessment occurred at
FIG. 1 Example ablative effects of intralesional PV-10 in treatment-
refractory melanoma. a Regional and close-up views of patient 0014,
male, age 48, with stage IIIB melanoma of the lower extremity
recurrent after 3 previous surgical interventions, treated once with
1.3 mL PV-10 into 10 target lesions on day 0 (bystander lesion B1
uninjected). All lesions were undetectable by ultrasound at week 24.
Possible recurrence of target lesions TL2, TL3, TL4, TL8, TL9, and
TL10 detected by ultrasound at week 36 (each 1–3 mm maximum
diameter; none sampled) with TL9 and TL10 remaining at week 52
(2–3 mm) without further treatment. Extensive eschar of TL2 and
TL3 within surgical scar is evident at day 7 with marked improve-
ment by week 4. Small (grade 1) treatment-emergent perilesional
blisters are evident in close-up view of TL8 at day 7. b Example of
treatment-emergent blisters occurring in 40 % of the patient popu-
lation and correlated with increased response rate of target lesions.
Generally presenting as tense bullae 1–7 days after treatment, blisters
typically resolved within 4 weeks with or without medication
intervention. Close-up views of patient 0204, female, age 82 years,
with stage IIIB melanoma of the lower extremity recurrent after four
previous surgical interventions, treated once with 0.8 mL PV-10 into
8 target lesions on day 0 (bystander lesion B1 uninjected). Grade 2
blistering developed in a surgical scar medial to target lesions TL3
and TL4 within 4 days, with full resolution within 1 week without
intervention
b
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week 8 and was repeated at each visit thereafter. Patients
failing to reach assessment at week 8 were deemed not
evaluable and classified as PD.
RESULTS
Patients
Eighty patients (intent-to-treat population, ITT; median
age 70 years, range 33–97 years; Table 1) were enrolled
over 19 months at 7 study centers: 3 in Australia and 4 in
the United States. All patients had recurrent, locally
advanced melanoma after a median of 6 previous inter-
ventions (range 1–19), and most had received multiple
classes of treatment. The median time from initial mela-
noma diagnosis to initial PV-10 treatment was 42.3 months
(range 1.7–752). Study lesions comprised a substantial total
tumor burden with a median sum of longest diameters of
6.3 cm (range 0.9–21.0 cm), with a median of 7.5 study
lesions per patient (range 1–22). The most prevalent
comorbidity was hypertension (51 % of patients), followed
by hypercholesterolemia (23 %) and depression (19 %).
Patients received a mean of 1.8 PV-10 treatment cycles
(median 2); 35 patients received a single cycle, and three
patients received the maximum four cycles allowed by
protocol.
Efficacy
Half of the ITT patients achieved an objective response in
their target lesions (51 % BORR, 26 % CR ? 25 % PR)
(Table 2), with 8 % of patients having no evidence of dis-
ease after 52 weeks. Locoregional disease control (SD or
better) was achieved in 69 % of patients, while 16 % were
not evaluable as a result of progression before week 8. (This
occurred predominantly in patients with extensive disease
burden not injected with PV-10.) Onset of response occurred
at a median of 1.9 months, corresponding with the
first assessment of response. The median duration of
response was 4.0 months (by RECIST) but was not met in the
study interval when assessed by mRECIST. Time-to-event
data for objective response are represented in Fig. 2, and PFS
data for all patients are summarized in Table 2.
Response rates by lesion among 491 target lesions in the
ITT population were similar to those by patient, with 53 %
of lesions achieving CR, 5 % PR, and 12 % SD.
Among the 42 patients with designated bystander lesions,
26 % experienced CR of their uninjected bystander lesions,
7 % PR, and 17 % SD. Response in bystander lesions strongly
correlated with that of patients’ target lesions: CR or PR in
target disease was associated with 56 % CR and 6 % PR in
bystander lesions; in contrast, patients who did not experience
an objective response of their target lesions had 6 % CR and
12 % PR of their bystander lesions (P = 0.023, BORR by v2
test).
Median OS was not reached for the ITT population.
Mean OS for stage III patients was [12 months (89 %
1-year survival, median not reached), while for stage IV
patients, median survival was 6.5 months (39 % 1-year
survival).
Because the protocol limited PV-10 treatment to the first
16 weeks, 11 patients subsequently withdrew to receive
further PV-10 treatment under alternative protocols.






\70 y 39 49






IV M1a 3 4
IV M1b 5 6
IV M1c 10 13
Treatment history
Prior therapy
Surgical excision 80 100
Nodal biopsy 50 63
Regional chemotherapy 19 24
Immunotherapy 17 21
Radiotherapy 17 21
Investigational agents 11 14
Systemic chemotherapy 10 13
Distal amputation 7 9
Other 6 8
No prior systemic therapy 45 56
Prior systemic therapy 35 44
Tumor burden in skin
\10 lesions 44 55
C10 lesions 29 36
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Safety
All patients experienced one or more AE during the
study (Table 3); most were grade 1 or grade 2, while 15 %
of patients had at least one grade 3 AE deemed at least
possibly related to study treatment. The most common AEs
occurred at the injection site, led by transient pain (reported
by 80 % of patients), edema (41 %), and vesicles (39 %).
Six patients experienced mild (4 %) or moderate (4 %)
injection site photosensitivity, and one (1 %) experienced a
severe generalized photosensitivity reaction. All of these
resolved without sequelae. No life-threatening or fatal AEs
at least possibly related to the study treatment were
reported.
Quality-of-life assessment throughout the study interval
showed no substantial change from baseline on any qual-
ity-of-life dimension after PV-10 treatment. Pain scores
indicated transient pain in treated lesions during the first
week after treatment that generally resolved to baseline
within 4 weeks. Approximately 60 % of patients received
local anesthesia at the time of PV-10 injection.
Pharmacokinetics
Pharmacokinetic data were consistent with the literature on
RB and illustrate PV-10 clearance via an apparent biexponential
process, with a rapid initial distribution/absorption phase
occurring during the first 24 h (kD/A = 0.0020 min
-1,
t1/2,D/A = 5.9 h), followed by slower terminal elimination
(kE = 0.00012 min
-1, t1/2,E = 100 h).
19 Relatively low uptake
during the initial phase (geometric mean %AUC? = 17.3 %)
and intercepts for the initial and terminal phases (427 and 73 ng/
mL, respectively) are consistent with prolonged retention of
drug in injected lesions, with potentially significant systemic
exposure only during the initial phase.
Untreated Disease Burden
Although only cutaneous and subcutaneous lesions were
injected, the study enrolled patients with stable visceral
disease (including brain, lung, and liver metastases) who
also had injectable dermal disease. To test for a relationship
of response to untreated disease burden, patients were
classified according to their reported tumor burden at base-
line: all known disease treated with PV-10 (28 patients); all
known disease treated with PV-10 (with the exception of 1–
2 uninjected bystander lesions) (26 patients); 10 or fewer
untreated and unmeasured dermal lesions (7 patients); and
dermal disease burden classified as too numerous to count or
as stage IV disease (19 patients). For the 54 patients in the
first two subgroups, their study lesions, including bystander
lesions, represented all documented disease at baseline.
These patients, who received PV-10 to all or substantially all
of their disease burden, achieved markedly higher response
rates compared to patients with substantial untreated disease
burden (Table 2).
TABLE 2 Objective response of target lesions
Patients categorized by disease burden at baseline










No. of patients 80 % 28 % 26 % 7 % 19 %
CR 21 26 14 50 6 23 1 14 0 0
PR 20 25 6 21 8 31 1 14 5 26
SD 14 18 3 11 8 31 1 14 2 11
PD (PD ? NEV)b 25 31 5 18 4 15 4 57 12 63
NEV: progression before week 8b 13 16 2 7 1 4 3 43 7 37
CR ? PR 41 51 20 71c 14 54 2 29 5 26
CR ? PR ? SD (locoregional disease control) 55 69 23 82 22 85 3 43 7 37
Mean PFS, mod 8.2 9.8e 8.9f 6.0 2.6
ITT intent to treat, TNTC too numerous to count, CR complete response, PR partial response, SD stable disease, PD progressive disease, NEV not
evaluable, PFS progression-free survival
a Median number of untreated lesions: 5
b Patients who were not evaluable were tracked separately but combined with PD for tabulation of outcome
c P = 0.006 vs. TNTC or stage IV subgroup, BORR by v2 test
d PFS by mRECIST, maximum follow-up duration 12 months
e P\ 0.01 vs. TNTC or stage IV subgroup, by log-rank test
f P = 0.04 vs. TNTC or stage IV subgroup, by log-rank test
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Locoregional Blistering
Another exploratory analysis was undertaken to under-
stand the relevance of locoregional vesicles (blistering).
Transient, fluid-filled bullae were observed in 40 % of
patients (23 % grade 1, 16 % grade 2, and 1 % grade 3,
including one occurrence reported as possible grade 1
photosensitivity), both perilesional and locoregional and
treatment emergent within 1–7 days of PV-10 administra-
tion. Onset was independent of dose with no apparent
relationship to prior PV-10 administration (Fig. 1). These
generally resolved within 4 weeks, with or without medi-
cation intervention and without long-term sequelae;
blistering was associated with a marked increase in
response: 44 % of patients with blisters experienced CR,
versus 15 % without blisters (P = 0.008).
Age, Sex, Treatment History, and Investigator
Exploratory analyses were undertaken to assess rele-
vance of demographics, treatment history, and investigator.
Equivalent target lesion responses occurred in patients
above and below the median age (54 vs. 49 % BORR,
P = 0.8) and for men and women (58 vs. 41 %, P = 0.2).
Dichotomization according to treatment history (systemic
or regional chemotherapy or immunotherapy vs. naive
patients) showed no significant difference in target lesion
response (43 vs. 58 %, P = 0.3). Similar response rates
were observed across study centers, with all centers
reporting at least one patient experiencing PR or better
(Fig. 2), and with five of the seven centers reporting
patients with no evidence of disease after 12 months.
Patterns of AEs were also similar across centers.
Visceral Disease
Although the study was not designed to quantitatively
follow lesions in visceral organs, comprehensive radiologic
imaging provided some insight into whether PV-10 could
have an impact on visceral disease. While a substantial
fraction patients with stage IV disease were classified as
not evaluable due to early progression (Table 2),
four patients experienced SD or PR of their visceral dis-
ease (including patients with multiple pleural and hepatic
metastases); three of these patients also exhibited SD or
better outcome in their target lesions, similar to the
correlation of bystander response to that of target lesions.
Seven stage IV patients survived through the end of the
























































Withdrawal for additional PV-10
Response ongoing at end of study
No evidence of disease
Last allowed PV-10 at week 16
FIG. 2 Temporal response of all
responding patients (i.e., CR or PR in
up to 10 cutaneous and subcutaneous
target lesions). The 21 patients who
experienced CR are shown in blue; the
16 stage III patients experiencing PR
are shown in white; and the 4 stage IV
patients experiencing PR are shown in
yellow. Black bands indicate time of
initial response. Patients who withdrew
early to receive further PV-10 treatment
under alternative protocols are
designated with a diamond; patients
with ongoing response at end of study
interval are designated with an arrow;
those with no evidence of disease at the
end of the study interval are designated
with a plus sign
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DISCUSSION
Patients enrolled onto this study had treatment-refrac-
tory cutaneous and subcutaneous metastatic melanoma
accessible to injection and were not candidates for systemic
therapy as a result of age, comorbidity, refractory disease,
or drug unavailability; one quarter had visceral metastases
plus injectable disease of the skin.
The primary ablative effect of PV-10 is evident upon
minimal intervention (Fig. 1a) and illustrates potentially
rapid durable disease control (Fig. 2). The predominantly
locoregional AE profile contrasts with global morbidities
reported for many systemic and emerging local thera-
pies.20–28 Response typically occurred after one or two PV-
10 treatment cycles versus six or more cycles for other
recent investigational IL therapies, with response observed
in treated and untreated disease.29–32
Untreated tumor burden had a major impact on response:
patients receiving injections to most or all tumor deposits
exhibited high rates of durable response, a trend that may
signify abrogation of immunosubversion by untreated tumor
burden.33–35 Simultaneous reduction of tumor burden and
immune stimulation with PV-10 has proven powerful in
animal models of metastasis, and correlation of response in
injected and uninjected disease in this and previous clinical
studies is consistent with such results.11,13 Emerging evi-
dence of a functional immune response secondary to ablation
(including increased levels of cytotoxic CD3? and CD8? T
cells in peripheral blood of patients refractory to immune
checkpoint inhibitors and targeted therapies) bolsters the
potential relevance of the observed bystander effect.12
Association of improved outcome with locoregional blis-
tering suggests that this AE deserves further investigation.
Three patients from this study experienced unexpectedly
positive responses upon subsequent radiotherapy of previ-
ously injected, uninjected, and new lesions.36 This
suggests that the combination of PV-10 with other treat-
ments may have merit in advanced-stage disease with
substantial tumor burden inaccessible to injection. In par-
ticular, the tumor-specific immune stimulation resulting
from PV-10 ablation is potentially additive or synergistic
with nonspecific immunotherapies.12,37
In summary, intralesional PV-10 elicited robust and
durable tumor regression in refractory cutaneous and subcu-
taneous melanoma with transient locoregional toxicity. The
primary ablative effect of PV-10 reduced the size of injected
tumors quickly, while regression of uninjected bystander
lesions is consistent with a secondary immune response.
These data suggest that PV-10 has utility in the management
of melanoma patients with injectable cutaneous and subcu-
taneous disease. Future studies will comprehensively assess
the effect of PV-10 on PFS to document potential longer-term
benefits of locoregional disease control.
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TABLE 3 Most frequent adverse events at least possibly related to
study treatment
System organ class and preferred terma Adverse eventsb (ITT





General disorders and administration site conditions
Injection site pain 29 25 10 64 80
Injection site edema 19 14 0 33 41
Injection site vesicles 17 13 1 31 39
Injection site discolorationc 13 12 0 25 31
Injection site swelling 14 7 1 22 28
Injection site pruritus 14 3 0 17 21
Injection site erythema 6 4 1 11 14
Injection site infection 3 2 1 6 8
Injection site inflammation 0 6 0 6 8
Injection site photosensitivity reactiond 3 3 0 6 8
Injection site ulcer 4 1 0 5 6
Peripheral edema 3 0 1 4 5
Fatigue 3 1 0 4 5
Injection site rash 4 0 0 4 5
Injection site warmth 2 2 0 4 5
Lethargy 3 1 0 4 5
Injection site cellulitis 0 2 1 3 4
Gastrointestinal disorders
Diarrhea 5 0 0 5 6
Nausea 2 3 0 5 6
Dysphagia 0 0 1 1 1
Nervous system disorders
Headache 11 2 0 13 16
Skin and subcutaneous tissue disorders
Photosensitivity reactiond 0 0 1 1 1
ITT intent to treat, CTCAE Common Terminology Criteria for
Adverse Events
a System organ class and preferred term are based on the MedDRA
version 13.0 terminology dictionary. Locoregional adverse events
were coded to ‘‘injection site’’ preferred terms to differentiate these
from systemic events
b Includes all AEs with an incidence of 5 % or higher and all CTCAE
grade 3 and higher AEs; there were no treatment-related grade 4 or 5
AEs reported. If a patient experienced an AE more than once during
the study, the greatest severity is presented
c Discoloration locoregional to injected lesions
d Combined incidence of injection site and skin and subcutaneous
tissue photosensitivity reactions: 9 %
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